PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
Search results for: baricitinib
Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare
The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.
What’s New in SLE: Pathogenesis & Novel Therapies
Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case
As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…
JAK Inhibitors: Are All Promises Fulfilled?
A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.
Difficult-to-Treat Lupus: When & How to Use New Therapies
Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.
Never Too Late: Late-Breaking Abstracts Create Excitement
EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…
Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients
In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…
The Ins & Outs of Patient Assistance Programs
Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »